4/A: Aldeyra Therapeutics Officer Amends Form 4 Filing to Correctly Report Stock Sale and ESPP Acquisition

Stephen Machatha, Chief Development Officer of Aldeyra Therapeutics, amends his Form 4 filing to accurately reflect a stock sale for tax purposes and an omission of shares acquired through the Employee Stock Purchase Plan.

Summary

• Stephen Machatha, Chief Development Officer of Aldeyra Therapeutics, filed an amended Form 4 with the SEC.
• The amendment corrects a previous filing from March 12, 2024, regarding a sale of common stock for tax withholding and planning purposes related to restricted stock unit settlements.
• The amended filing also includes 9,317 shares of common stock acquired under the company's Employee Stock Purchase Plan (ESPP), which were initially omitted.
• The shares were sold in multiple transactions at prices ranging from $3.11 to $3.31, with a weighted average sales price of $3.164.
• Following the reported transactions, Machatha beneficially owns 252,812 shares of Aldeyra Therapeutics common stock.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing. The sentiment is neutral as it simply corrects previously reported information.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.

Key Dates